Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression.
Hwang
Yu-Yan
YY
Wong
Kai Y
KY
Leung
Rock Y Y
RY
Wong
Simon H M
SH
Chan
See-Ching
SC
Srivastava
Gopesh
G
Au
Wing Y
WY
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000235:genetics / Q000378:metabolism*; D001483:Base Sequence; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology*; D017809:Fatal Outcome; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000096:biosynthesis / Q000235:genetics; D016031:Liver Transplantation / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D008969:Molecular Sequence Data; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007147:Immunoglobulin Light Chains; D000069283:Rituximab